Is Qiagen profitable in 2026?

Yes. Qiagen reported FY2025 net income of $424.9 million, up sharply from $83.6 million in FY2024, as of December 31, 2025. However, FY2026 EPS guidance was cut to $2.43 from $2.50 on April 27, 2026, reflecting softer QuantiFERON demand and cautious life-sciences capex.

Is Qiagen being acquired?

Not confirmed yet. Bloomberg reported July 9, 2026 that private equity firms EQT, Advent International and KKR were exploring a takeover of Qiagen, with bids reportedly at $50 or more per share; shares jumped 10 to 14 percent intraday. Qiagen had retained Moelis and Goldman Sachs since January 2026 to review strategic alternatives, but no deal has closed.

Who is Qiagen's biggest competitor?

Qiagen competes in a consolidated molecular diagnostics oligopoly alongside Thermo Fisher Scientific, Roche, Danaher and Abbott, which together held roughly 60 percent collective market share in 2025 according to a June 30, 2026 industry market report. No single rival is reported actively taking share from Qiagen as of mid 2026.

Could AI replace Qiagen?

Unlikely for its core business. Qiagen's regulated hardware and consumables lock-in, with over 5,200 QIAstat-Dx and 3,200 QIAcuity instruments placed worldwide by end of 2025, requires regulatory revalidation AI cannot bypass. Its bioinformatics interpretation layer (QCI Interpret, Franklin) is more exposed, but is shielded by curated proprietary genomic databases.

Is Qiagen laying off employees?

Headcount has drifted down modestly: Qiagen's own reporting shows about 5,700 employees at December 31, 2025 falling to about 5,500 by March 31, 2026, alongside a hiring slowdown, though no mass layoff announcement has been reported.

Qiagen N.V. is publicly traded with no controlling parent, listed as NYSE: QGEN and Frankfurt Prime Standard: QIA, with a market capitalization of roughly $8.5 to $8.7 billion as of July 24, 2026, amid reported private-equity takeover interest.

Biotech tools companies · Germany

Qiagen

qiagen.com ↗

Maker of sample prep and molecular test kits like QIAstat-Dx and QIAcuity for labs and hospitals.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from August 5, 2026 · Every call on the record Checkpoint: Q2 2026 earnings release, watched for whether revenue guidance stabilizes or worsens

The call

Qiagen sits on a large installed base of testing hardware that is hard to rip out, while takeover talks from EQT, Advent and KKR now shape its near-term ownership more than any AI rival does.

Qiagen makes machines and tests that help labs diagnose diseases by analyzing DNA and other molecules. It is hard to replace because thousands of labs have already bought their machines and would need expensive new equipment plus government approval to switch to a competitor like Bio-Rad or Roche. The company's growth has slowed down and private equity firms are bidding to buy it, which could either cap how much the stock rises or force it to cut costs and emerge as a smaller public company.

Why

AI pressure: AI-driven diagnostic interpretation platforms such as Tempus AI. AI tools that read genomic and pathogen data directly could shrink demand for Qiagen's own bioinformatics software layer. Could AI do the core job? Unlikely.

Bigger players: Thermo Fisher Scientific. Thermo Fisher already sells competing PCR, sample prep and sequencing kits into the same hospital and lab accounts. Could a giant copy it? Probably.

What protects it. Over 5,200 QIAstat-Dx and 3,200 QIAcuity instruments already installed, each locking in consumables and requiring costly re-validation to switch.

What would change this call

Q2 2026 earnings release on Aug 5, 2026 shows revenue growth stabilizing or turning negative. Would show whether the demand slowdown is bottoming out or worsening.
EQT, Advent, or KKR announce a signed takeover agreement for Qiagen or formally walk away. Would show whether equity holders face a capped buyout price or continued public-market risk.
Qiagen names a permanent CEO successor and outlines strategy in H2 2026. Would show whether leadership transition preserves or disrupts strategic continuity.

Key numbers

FY2025 net income $424.9M, up from $83.6M in FY2024 (2025-12-31)
Over 5,200 QIAstat-Dx units placed worldwide (2025-12-31)
Market cap around $8.5-8.7 billion (2026-07-24)

Named risks

PE takeover (EQT/Advent/KKR) could cap equity upside or trigger cost restructuring. Severity: high
CEO transition in H2 2026 coincides with active takeover speculation. Severity: medium
FY2026 guidance cut and near-flat Q1 2026 revenue signal stalled growth. Severity: medium
Softer QuantiFERON demand and cautious U.S. life-sciences capex pressure sales. Severity: medium
Parse Biosciences acquisition dilutive by ~$0.04 EPS in 2026 before turning accretive in 2028. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Thermo Fisher Scientific	contesting	Top-5 molecular diagnostics oligopoly with ~60% collective share, 2025
Roche	contesting	Co-leader in molecular diagnostics oligopoly as of 2025
Danaher	contesting	Cepheid/Beckman Coulter units compete in same diagnostics oligopoly, 2025
Abbott Laboratories	contesting	Part of top-5 group holding ~60% collective market share, 2025
10x Genomics	contesting	Qiagen bought Parse Biosciences Nov 2025 to compete in single-cell genomics

Questions people ask

Is Qiagen profitable in 2026?: Yes. Qiagen reported FY2025 net income of $424.9 million, up sharply from $83.6 million in FY2024, as of December 31, 2025. However, FY2026 EPS guidance was cut to $2.43 from $2.50 on April 27, 2026, reflecting softer QuantiFERON demand and cautious life-sciences capex.
Is Qiagen being acquired?: Not confirmed yet. Bloomberg reported July 9, 2026 that private equity firms EQT, Advent International and KKR were exploring a takeover of Qiagen, with bids reportedly at $50 or more per share; shares jumped 10 to 14 percent intraday. Qiagen had retained Moelis and Goldman Sachs since January 2026 to review strategic alternatives, but no deal has closed.
Who is Qiagen's biggest competitor?: Qiagen competes in a consolidated molecular diagnostics oligopoly alongside Thermo Fisher Scientific, Roche, Danaher and Abbott, which together held roughly 60 percent collective market share in 2025 according to a June 30, 2026 industry market report. No single rival is reported actively taking share from Qiagen as of mid 2026.
Could AI replace Qiagen?: Unlikely for its core business. Qiagen's regulated hardware and consumables lock-in, with over 5,200 QIAstat-Dx and 3,200 QIAcuity instruments placed worldwide by end of 2025, requires regulatory revalidation AI cannot bypass. Its bioinformatics interpretation layer (QCI Interpret, Franklin) is more exposed, but is shielded by curated proprietary genomic databases.
Is Qiagen laying off employees?: Headcount has drifted down modestly: Qiagen's own reporting shows about 5,700 employees at December 31, 2025 falling to about 5,500 by March 31, 2026, alongside a hiring slowdown, though no mass layoff announcement has been reported.
Who owns Qiagen?: Qiagen N.V. is publicly traded with no controlling parent, listed as NYSE: QGEN and Frankfurt Prime Standard: QIA, with a market capitalization of roughly $8.5 to $8.7 billion as of July 24, 2026, amid reported private-equity takeover interest.

Timeline

2026-07-09Bloomberg reports EQT, Advent and KKR exploring takeover, bids reportedly at $50+/share
2026-05-12Additional $200M synthetic share buyback authorized; governance renewal announced at AGM
2026-04-27FY2026 EPS guidance cut to $2.43 from $2.50
2026-04-15Employee count reported at ~5,500; bloodstream infection testing expansion announced
2026-04-01Outgoing CEO Thierry Bernard joins Bruker's board of directors
2026-01-12Qiagen sets 2026 priorities; QIAcuity placements exceed 3,200 units
2026-01Bloomberg reports Qiagen exploring sale, retains Moelis and Goldman Sachs
2025-11-05Agrees to acquire Parse Biosciences for $225M upfront plus $55M milestones
2025-11CEO Thierry Bernard announces he will step down once successor named
2025-05-12Acquires Genoox, adding AI clinical genomics platform Franklin

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE